IO Biotech Files 8-K

Ticker: IOBT · Form: 8-K · Filed: Aug 30, 2024 · CIK: 1865494

Io Biotech, Inc. 8-K Filing Summary
FieldDetail
CompanyIo Biotech, Inc. (IOBT)
Form Type8-K
Filed DateAug 30, 2024
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

IO Biotech filed an 8-K, check for updates.

AI Summary

IO Biotech, Inc. filed an 8-K on August 30, 2024, reporting on other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates that IO Biotech, Inc. has made a regulatory submission to the SEC, which may contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K without immediate disclosed material events or financial impacts.

Key Players & Entities

  • IO Biotech, Inc. (company) — Registrant
  • August 30, 2024 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • +45 7070 2980 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing for IO Biotech, Inc.?

The 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, filed on August 30, 2024, to report on other events and financial statements.

What is the exact name of the company filing this report?

The exact name of the Registrant is IO Biotech, Inc.

In which state was IO Biotech, Inc. incorporated?

IO Biotech, Inc. was incorporated in Delaware.

What is the principal executive office address of IO Biotech, Inc.?

The address of the principal executive offices is Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.

What is the telephone number for IO Biotech, Inc.?

The Registrant's telephone number, including area code, is +45 7070 2980.

Filing Stats: 678 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2024-08-30 16:10:54

Key Financial Figures

  • $0.001 — ich registered Common Stock, par value $0.001 per share IOBT The Nasdaq Stock Mar

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 IO Biotech, Inc. Press Release, dated as of August 30, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IO BIOTECH, INC. Date: August 30, 2024 By: /s/ Mai-Britt Zocca, Ph.D. Name: Mai-Britt Zocca, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.